Trial

Phase 1, Partially-Blind, Placebo Controlled Randomized, Combined SAD With Food Effect Cohort and MAD and DDI Study to Evaluate Safety, Tolerability, PK and PK Interaction Between TBA-7371 With Midazolam and Bupropion in Healthy Subjects

Study Director
Paul Bruinenberg, MD
Start Date
8 / 2017
Trial Phase
Phase I
Trial Status
in data analysis
Current Enrollment
74 (July 2018)
Target Enrollment
92
Overview

The primary objective of the study was to evaluate the safety and tolerability of single and multiple doses of TBA-7371 in healthy subjects.

The trial completed in July 2018, with no results published since. TBA-7371 has since been tested in a Phase 2a study (https://clinicaltrials.gov/study/NCT04176250).

Registry Link
Developer Associations
TB Alliance
Compound Associations
TBA-7371